½ÃÀ庸°í¼­
»óǰÄÚµå
1547800

¼¼°èÀÇ Àü¿¢¼Ø ½ÃÄö½Ì ½ÃÀå Á¶»ç º¸°í¼­ : »ê¾÷ ºÐ¼®, ±Ô¸ð, Á¡À¯À², ¼ºÀå, µ¿Çâ, ¿¹Ãø(2024-2032³â)

Global Whole Exome Sequencing Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Value Market Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 222 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ Àü¿¢¼Ø ½ÃÄö½Ì ½ÃÀå ¼ö¿ä´Â Á¶»ç±â°£ 2024³âºÎÅÍ 2032³â±îÁö CAGR 18.21%·Î Àü¸ÁµÇ¸ç, 2023³â 4¾ï 3,002¸¸ ´Þ·¯¿¡¼­ 2032³â¿¡´Â ¾à 19¾ï 3,812¸¸ ´Þ·¯ ±Ô¸ð¿¡ À̸¦ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù.

Àü¿¢¼Ø ½ÃÄö½Ì ¶Ç´Â ¿¢¼Ø ½ÃÄö½Ì´Â À¯ÀüüÀÇ ´Ü¹éÁú ÄÚµù ¿µ¿ªÀÇ ½ÃÄö½Ì¿¡ »ç¿ëµÇ´Â Â÷¼¼´ë ½ÃÄö½Ì ¹æ¹ý(NGS)ÀÔ´Ï´Ù. Àü¿¢¼Ø ½ÃÄö½Ì¿¡´Â µÎ ´Ü°è°¡ ÀÖ½À´Ï´Ù. ù ¹øÂ° ´Ü°è´Â ´Ü¹éÁúÀ» ÄÚµùÇÏ´Â DNAÀÇ ÇÏÀ§ ÁýÇÕÀ» ¼±ÅÃÇÏ°í µÎ ¹øÂ° ´Ü°è´Â ¿¢¼Õ DNAÀÇ ½ÃÄö½ÌÀÔ´Ï´Ù. ÀÌ ½ÃÄö½Ì ¹æ¹ýÀº ÀÓ»ó Áø´Ü ¹× Çмú ¿¬±¸¿¡ »ç¿ëµË´Ï´Ù. ´Ü¹éÁú ¼­¿­ÀÇ º¯È­¸¦ ÀÏÀ¸Å°´Â À¯ÀüÀÚÄÚµù º¯ÇüÀ» È®ÀÎÇÕ´Ï´Ù. Ȧ À¯Àüü ½ÃÄö½ÌÀº ¾Ï ¿¬±¸, À¯Àü¼º ÁúȯÀÇ ¿øÀÎÀÌ µÇ´Â À¯ÀüÀÚ º¯ÀÌÀÇ ÀÌÇØ¿Í µ¿Á¤, Áý´Ü À¯ÀüÇÐÀÇ ÀÌÇØ¿¡ ¸Å¿ì ÀûÇÕÇÕ´Ï´Ù.

½ÃÀå ¿ªÇÐ

¹Ì·¯ ÁõÈıº°ú ¾ËÃ÷ÇÏÀ̸Ӻ´°ú °°Àº À¯Àü¼º Áúȯ¿¡ ´ëÇÑ ÀǽÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó ¼¼°èÀÇ Àü¿¢¼Ø ½ÃÄö½Ì ½ÃÀåÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù. Àü¿¢¼Ø ½ÃÄö½ÌÀº Ȧ À¯Àüü ½ÃÄö½ÌÀ» ´ëüÇÏ´Â ºñ¿ë È¿À²ÀûÀÎ ±â¼úÀÔ´Ï´Ù. µû¶ó¼­ Àúºñ¿ë°ú °í¼Ó¼ºÀº ¼¼°èÀÇ Àü¿¢¼Ø ½ÃÄö½Ì ½ÃÀåÀ» °ßÀÎÇÏ´Â µÎ °¡Áö ¿äÀÎÀÔ´Ï´Ù. ½ÃÀåÀ» °ßÀÎÇÏ´Â ´Ù¸¥ ÇöÀúÇÑ ¿äÀÎÀ¸·Î´Â ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ Ã¤¿ë Áõ°¡, ¸¸¼º ÁúȯÀÇ Áõ·Ê Áõ°¡, À¯Àüü ½ÃÄö½Ì¿¡¼­ R&D Áõ°¡ µîÀÌ ÀÖ½À´Ï´Ù. °Ô´Ù°¡ ±â¼úÀÇ Áøº¸, Çõ½ÅÀûÀÎ °úÇÐÀû ÀÀ¿ë Áõ°¡, ±âÁ¸ ÁÖ¿ä ±â¾÷ÀÇ ÅõÀÚ Áõ°¡, ½Å±Ô ±â¾÷ ½ÃÀå ÁøÀÔ µîÀÇ ¿äÀεµ ½ÃÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

Á¶»ç º¸°í¼­´Â Porter's Five Forces ¸ðµ¨, ½ÃÀå ¸Å·Â ºÐ¼® ¹× ¹ë·ùüÀÎ ºÐ¼®À» ´Ù·ì´Ï´Ù. ÀÌ·¯ÇÑ µµ±¸´Â ¾÷°èÀÇ ±¸Á¶¸¦ ¸íÈ®ÇÏ°Ô ÆÄ¾ÇÇÏ°í ¼¼°è ¼öÁØÀÇ °æÀïÀÇ ¸Å·ÂÀ» Æò°¡ÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. °Ô´Ù°¡, ÀÌ·¯ÇÑ µµ±¸´Â ¼¼°èÀÇ Àü¿¢¼Ø ½ÃÄö½Ì ½ÃÀå¿¡¼­ °¢ ºÎ¹®À» Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. Àü¿¢¼Ø ½ÃÄö½Ì »ê¾÷ÀÇ ¼ºÀå°ú µ¿ÇâÀº ÀÌ ¿¬±¸¿¡ ´ëÇÑ Àü¹ÝÀûÀÎ Á¢±Ù¹ýÀ» ¼³¸íÇÕ´Ï´Ù.

½ÃÀå ¼¼ºÐÈ­

Àü¿¢¼Ø ½ÃÄö½Ì ½ÃÀå º¸°í¼­ÀÇ ÀÌ ¼½¼Ç¿¡¼­´Â ±¹°¡ ¹× Áö¿ª ¼öÁØ ºÎ¹®¿¡ ´ëÇÑ ÀÚ¼¼ÇÑ µ¥ÀÌÅ͸¦ Á¦°øÇÏ¿© Àü·«°¡°¡ ÇâÈÄ ±âȸ¸¦ °¡Áø °¢ Á¦Ç° ¹× ¼­ºñ½ºÀÇ ´ë»ó °èÃþÀ» ÆÄ¾ÇÇÒ ¼ö ÀÖµµ·Ï µµ¿ÍÁÝ´Ï´Ù.

Áö¿ª ºÐ¼®

ÀÌ ¼½¼Ç¿¡¼­´Â ºÏ¹Ì, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ Àü¿¢¼Ø ½ÃÄö½Ì ½ÃÀåÀÇ ÇöÀç ¹× ¹Ì·¡ ¼ö¿ä¸¦ °­Á¶ÇÏ´Â Áö¿ª Àü¸ÁÀ» ´Ù·ì´Ï´Ù. ¶ÇÇÑ ÀÌ º¸°í¼­´Â ¸ðµç ÁÖ¿ä Áö¿ª¿¡¼­ °³º° ¿ëµµ ºÎ¹® ¼ö¿ä, ÃßÁ¤ ¹× ¿¹Ãø¿¡ ÁßÁ¡À» µÓ´Ï´Ù.

¸ÂÃ㠿䱸»çÇ×ÀÌ ÀÖ´Â °æ¿ì Google¿¡ ¹®ÀÇÇϼ¼¿ä. ´ç»çÀÇ ¼³¹®Á¶»çÆÀÀº °í°´ÀÇ ¿ä±¸¿¡ µû¶ó ¸ÂÃãÇü º¸°í¼­¸¦ Á¦°øÇÒ ¼ö ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå ÁÖ¿ä ¿ä¾à

  • ½ÃÀåÀÇ ÇÏÀ̶óÀÌÆ®
  • ¼¼°è ½ÃÀå ÇöȲ

Á¦3Àå Àü¿¢¼Ø ½ÃÄö½Ì : »ê¾÷ ºÐ¼®

  • ¼­¹® : ½ÃÀå ¿ªÇÐ
  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
  • ±âȸ
  • ¾÷°è µ¿Çâ
  • Porter's Five Forces ºÐ¼®
  • ½ÃÀåÀÇ ¸Å·Â ºÐ¼®

Á¦4Àå ¹ë·ùüÀÎ ºÐ¼®

  • ¹ë·ùüÀÎ ºÐ¼®
  • ¿øÀç·á ºÐ¼®
    • ¿øÀç·á ¸®½ºÆ®
    • ¿øÀç·á Á¦Á¶¾÷ü À϶÷
    • ÁÖ¿ä ¿øÀç·áÀÇ °¡°Ý µ¿Çâ
  • ÀáÀçÀû ¹ÙÀ̾î À϶÷
  • ¸¶ÄÉÆÃ Ã¤³Î
    • Á÷Á¢ ¸¶ÄÉÆÃ
    • °£Á¢ ¸¶ÄÉÆÃ
    • ¸¶ÄÉÆÃ Ã¤³Î ¹ßÀü µ¿Çâ

Á¦5Àå ¼¼°èÀÇ Àü¿¢¼Ø ½ÃÄö½Ì ½ÃÀå ºÐ¼® : Á¦Ç°º°

  • °³¿ä : Á¦Ç°º°
  • ½ÇÀû µ¥ÀÌÅÍ ¹× ¿¹Ãø µ¥ÀÌÅÍ
  • ºÐ¼® : Á¦Ç°º°
  • ±â±â
  • ¼Ò¸ðǰ
  • ¼­ºñ½º

Á¦6Àå ¼¼°èÀÇ Àü¿¢¼Ø ½ÃÄö½Ì ½ÃÀå ºÐ¼® : ±â¼úº°

  • °³¿ä : ±â¼úº°
  • ½ÇÀû µ¥ÀÌÅÍ ¹× ¿¹Ãø µ¥ÀÌÅÍ
  • ºÐ¼® : ±â¼úº°
  • ÇÕ¼º ½ÃÄö½Ì
  • À̿ ¹ÝµµÃ¼ ½ÃÄö½Ì
  • ±âŸ

Á¦7Àå ¼¼°èÀÇ Àü¿¢¼Ø ½ÃÄö½Ì ½ÃÀå ºÐ¼® : ¿öÅ©Ç÷ο캰

  • °³¿ä : ¿öÅ©Ç÷ο캰
  • ½ÇÀû µ¥ÀÌÅÍ ¹× ¿¹Ãø µ¥ÀÌÅÍ
  • ºÐ¼® : ¿öÅ©Ç÷ο캰
  • »çÀü ½ÃÄö½Ì
  • ½ÃÄö½Ì
  • µ¥ÀÌÅÍ ºÐ¼®

Á¦8Àå ¼¼°èÀÇ Àü¿¢¼Ø ½ÃÄö½Ì ½ÃÀå ºÐ¼® : ¿ëµµº°

  • °³¿ä : ¿ëµµº°
  • ½ÇÀû µ¥ÀÌÅÍ ¹× ¿¹Ãø µ¥ÀÌÅÍ
  • ºÐ¼® : ¿ëµµº°
  • ÀÓ»ó Áø´Ü
  • â¾à ¹× ÀǾàǰ °³¹ß
  • °³º°È­ ÀǾàǰ
  • ±âŸ

Á¦9Àå ¼¼°èÀÇ Àü¿¢¼Ø ½ÃÄö½Ì ½ÃÀå ºÐ¼® : ÃÖÁ¾ ¿ëµµº°

  • °³¿ä : ÃÖÁ¾ ¿ëµµº°
  • ½ÇÀû µ¥ÀÌÅÍ ¹× ¿¹Ãø µ¥ÀÌÅÍ
  • ºÐ¼® : ÃÖÁ¾ ¿ëµµº°
  • Çмú¿¬±¸±â°ü
  • º´¿ø ¹× Ŭ¸®´Ð
  • Á¦¾à ¹× ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷
  • ±âŸ

Á¦10Àå ¼¼°èÀÇ Àü¿¢¼Ø ½ÃÄö½Ì ½ÃÀå ºÐ¼® : Áö¿ªº°

  • Áö¿ªº° Àü¸Á
  • ¼­¹®
  • ºÏ¹ÌÀÇ ¸ÅÃ⠺м®
    • °³¿ä, ºÐ¼® ¹× ¿¹Ãø
    • ºÏ¹Ì : ºÎ¹®º°
    • ºÏ¹Ì : ±¹°¡º°
    • ¹Ì±¹
    • ij³ª´Ù
    • ¸ß½ÃÄÚ
  • À¯·´ÀÇ ¸ÅÃ⠺м®
    • °³¿ä, ºÐ¼® ¹× ¿¹Ãø
    • À¯·´ : ºÎ¹®º°
    • À¯·´ : ±¹°¡º°
    • ¿µ±¹
    • ÇÁ¶û½º
    • µ¶ÀÏ
    • ÀÌÅ»¸®¾Æ
    • ·¯½Ã¾Æ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ¸ÅÃ⠺м®
    • °³¿ä, ºÐ¼® ¹× ¿¹Ãø
    • ¾Æ½Ã¾ÆÅÂÆò¾ç : ºÎ¹®º°
    • ¾Æ½Ã¾ÆÅÂÆò¾ç : ±¹°¡º°
    • Áß±¹
    • Àεµ
    • ÀϺ»
    • Çѱ¹
    • È£ÁÖ
    • µ¿³²¾Æ½Ã¾Æ
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«ÀÇ ¸ÅÃ⠺м®
    • °³¿ä, ºÐ¼® ¹× ¿¹Ãø
    • ¶óƾ¾Æ¸Þ¸®Ä« : ºÎ¹®º°
    • ¶óƾ¾Æ¸Þ¸®Ä« : ±¹°¡º°
    • ºê¶óÁú
    • ¾Æ¸£ÇîÆ¼³ª
    • Æä·ç
    • Ä¥·¹
    • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ¸ÅÃ⠺м®
    • °³¿ä, ºÐ¼® ¹× ¿¹Ãø
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : ºÎ¹®º°
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : ±¹°¡º° À϶÷
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
    • À̽º¶ó¿¤
    • ³²¾ÆÇÁ¸®Ä«
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦11Àå Àü¿¢¼Ø ½ÃÄö½Ì ±â¾÷ °æÀï ±¸µµ

  • Àü¿¢¼Ø ½ÃÄö½Ì ½ÃÀåÀÇ °æÀï
  • ÆÄÆ®³Ê½Ê, Á¦ÈÞ ¹× ÇÕÀÇ
  • ÇÕº´ ¹× Àμö
  • ½ÅÁ¦Ç° Ãâ½Ã
  • ±âŸ °³¹ß

Á¦12Àå ±â¾÷ ÇÁ·ÎÆÄÀÏ

  • ÁÖ¿ä ±â¾÷ÀÇ ½ÃÀå Á¡À¯À² ºÐ¼®
  • ½ÃÀå ÁýÁßµµ
  • Thermo Fisher Scientific Inc.
  • Illumina Inc
  • Agilent Technologies Inc
  • BGI
  • PacBio
  • Oxford Nanopore Technologies Plc.
  • Azenta US Inc.(Genewiz)
  • CD Genomics
  • Novogene Co Ltd
  • Eurofins Genomics
AJY 24.09.30

The global demand for Whole Exome Sequencing Market is presumed to reach the market size of nearly USD 1938.12 Million by 2032 from USD 430.02 Million in 2023 with a CAGR of 18.21% under the study period 2024-2032.

Whole Exome Sequencing or Exome Sequencing is a next-generation sequencing method (NGS) used for sequencing of the protein-coding regions of the genome. Whole Exome Sequencing involves two steps - the first step is the selection of the subset of DNA, which encodes proteins, and the second step is the sequencing of the exonic DNA. The sequencing method is used in clinical diagnostics and academic research. It identifies genetic coding variants responsible for alteration in protein sequencing. Whole-genome sequencing is highly applicable in cancer research, understanding and identification of genetic variants causing genetic diseases, and understanding population genetics.

MARKET DYNAMICS

The global Whole Exome Sequencing market is expanding due to increasing awareness about genetic diseases such as Miller's syndrome and Alzheimer's disease. Whole Exome Sequencing is a cost-effective alternative for Whole-genome sequencing. Hence low cost and high speed are the two factors that are triggering the global Whole Exome Sequencing market. The other prominent factors that are driving the market include rising adoption for personalized medicine, growing cases of chronic diseases and growing R & D in genome sequencing. Moreover, factors such as advancement in technology, a growing number of innovative scientific applications, increasing investments by existing key players, and entry of new companies in the market are also propelling the market.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Whole Exome Sequencing. The growth and trends of Whole Exome Sequencing industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Whole Exome Sequencing market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Product

  • Instruments
  • Consumables
  • Services

By Technology

  • Sequencing by Synthesis
  • ION Semiconductor Sequencing
  • Others

By Workflow

  • Pre-Sequencing
  • Sequencing
  • Data Analysis

By Application

  • Clinical Diagnostics
  • Drug Discovery & Development
  • Personalized Medicines
  • Others

By End-use

  • Academic And Research Institutes
  • Hospitals & Clinics
  • Pharmaceutical & Biotechnology Companies
  • Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Whole Exome Sequencing market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Whole Exome Sequencing market include Thermo Fisher Scientific Inc., Illumina Inc, Agilent Technologies Inc, BGI, PacBio, Oxford Nanopore Technologies Plc., Azenta US Inc. (Genewiz), CD Genomics, Novogene Co Ltd, Eurofins Genomics. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Report Description
    • 1.1.1 Objective
    • 1.1.2 Target Audience
    • 1.1.3 Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1 Market Research Process
    • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3. WHOLE EXOME SEQUENCING - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Product
    • 3.7.2 Market Attractiveness Analysis By Technology
    • 3.7.3 Market Attractiveness Analysis By Workflow
    • 3.7.4 Market Attractiveness Analysis By Application
    • 3.7.5 Market Attractiveness Analysis By End-use
    • 3.7.6 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1 List of Raw Materials
    • 4.2.2 Raw Material Manufactures List
    • 4.2.3 Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1 Direct Marketing
    • 4.4.2 Indirect Marketing
    • 4.4.3 Marketing Channel Development Trend

5. GLOBAL WHOLE EXOME SEQUENCING MARKET ANALYSIS BY PRODUCT

  • 5.1. Overview By Product
  • 5.2. Historical and Forecast Data
  • 5.3. Analysis By Product
  • 5.4. Instruments Historic and Forecast Sales By Regions
  • 5.5. Consumables Historic and Forecast Sales By Regions
  • 5.6. Services Historic and Forecast Sales By Regions

6. GLOBAL WHOLE EXOME SEQUENCING MARKET ANALYSIS BY TECHNOLOGY

  • 6.1. Overview By Technology
  • 6.2. Historical and Forecast Data
  • 6.3. Analysis By Technology
  • 6.4. Sequencing by Synthesis Historic and Forecast Sales By Regions
  • 6.5. ION Semiconductor Sequencing Historic and Forecast Sales By Regions
  • 6.6. Others Historic and Forecast Sales By Regions

7. GLOBAL WHOLE EXOME SEQUENCING MARKET ANALYSIS BY WORKFLOW

  • 7.1. Overview By Workflow
  • 7.2. Historical and Forecast Data
  • 7.3. Analysis By Workflow
  • 7.4. Pre-Sequencing Historic and Forecast Sales By Regions
  • 7.5. Sequencing Historic and Forecast Sales By Regions
  • 7.6. Data Analysis Historic and Forecast Sales By Regions

8. GLOBAL WHOLE EXOME SEQUENCING MARKET ANALYSIS BY APPLICATION

  • 8.1. Overview By Application
  • 8.2. Historical and Forecast Data
  • 8.3. Analysis By Application
  • 8.4. Clinical Diagnostics Historic and Forecast Sales By Regions
  • 8.5. Drug Discovery & Development Historic and Forecast Sales By Regions
  • 8.6. Personalized Medicines Historic and Forecast Sales By Regions
  • 8.7. Others Historic and Forecast Sales By Regions

9. GLOBAL WHOLE EXOME SEQUENCING MARKET ANALYSIS BY END-USE

  • 9.1. Overview By End-use
  • 9.2. Historical and Forecast Data
  • 9.3. Analysis By End-use
  • 9.4. Academic And Research Institutes Historic and Forecast Sales By Regions
  • 9.5. Hospitals & Clinics Historic and Forecast Sales By Regions
  • 9.6. Pharmaceutical & Biotechnology Companies Historic and Forecast Sales By Regions
  • 9.7. Others Historic and Forecast Sales By Regions

10. GLOBAL WHOLE EXOME SEQUENCING MARKET ANALYSIS BY GEOGRAPHY

  • 10.1. Regional Outlook
  • 10.2. Introduction
  • 10.3. North America Sales Analysis
    • 10.3.1 Overview, Historic and Forecast Data Sales Analysis
    • 10.3.2 North America By Segment Sales Analysis
    • 10.3.3 North America By Country Sales Analysis
    • 10.3.4 United States Sales Analysis
    • 10.3.5 Canada Sales Analysis
    • 10.3.6 Mexico Sales Analysis
  • 10.4. Europe Sales Analysis
    • 10.4.1 Overview, Historic and Forecast Data Sales Analysis
    • 10.4.2 Europe By Segment Sales Analysis
    • 10.4.3 Europe By Country Sales Analysis
    • 10.4.4 United Kingdom Sales Analysis
    • 10.4.5 France Sales Analysis
    • 10.4.6 Germany Sales Analysis
    • 10.4.7 Italy Sales Analysis
    • 10.4.8 Russia Sales Analysis
    • 10.4.9 Rest Of Europe Sales Analysis
  • 10.5. Asia Pacific Sales Analysis
    • 10.5.1 Overview, Historic and Forecast Data Sales Analysis
    • 10.5.2 Asia Pacific By Segment Sales Analysis
    • 10.5.3 Asia Pacific By Country Sales Analysis
    • 10.5.4 China Sales Analysis
    • 10.5.5 India Sales Analysis
    • 10.5.6 Japan Sales Analysis
    • 10.5.7 South Korea Sales Analysis
    • 10.5.8 Australia Sales Analysis
    • 10.5.9 South East Asia Sales Analysis
    • 10.5.10 Rest Of Asia Pacific Sales Analysis
  • 10.6. Latin America Sales Analysis
    • 10.6.1 Overview, Historic and Forecast Data Sales Analysis
    • 10.6.2 Latin America By Segment Sales Analysis
    • 10.6.3 Latin America By Country Sales Analysis
    • 10.6.4 Brazil Sales Analysis
    • 10.6.5 Argentina Sales Analysis
    • 10.6.6 Peru Sales Analysis
    • 10.6.7 Chile Sales Analysis
    • 10.6.8 Rest of Latin America Sales Analysis
  • 10.7. Middle East & Africa Sales Analysis
    • 10.7.1 Overview, Historic and Forecast Data Sales Analysis
    • 10.7.2 Middle East & Africa By Segment Sales Analysis
    • 10.7.3 Middle East & Africa By Country Sales Analysis
    • 10.7.4 Saudi Arabia Sales Analysis
    • 10.7.5 UAE Sales Analysis
    • 10.7.6 Israel Sales Analysis
    • 10.7.7 South Africa Sales Analysis
    • 10.7.8 Rest Of Middle East And Africa Sales Analysis

11. COMPETITIVE LANDSCAPE OF THE WHOLE EXOME SEQUENCING COMPANIES

  • 11.1. Whole Exome Sequencing Market Competition
  • 11.2. Partnership/Collaboration/Agreement
  • 11.3. Merger And Acquisitions
  • 11.4. New Product Launch
  • 11.5. Other Developments

12. COMPANY PROFILES OF WHOLE EXOME SEQUENCING INDUSTRY

  • 12.1. Top Companies Market Share Analysis
  • 12.2. Market Concentration Rate
  • 12.3. Thermo Fisher Scientific Inc.
    • 12.3.1 Company Overview
    • 12.3.2 Company Revenue
    • 12.3.3 Products
    • 12.3.4 Recent Developments
  • 12.4. Illumina Inc
    • 12.4.1 Company Overview
    • 12.4.2 Company Revenue
    • 12.4.3 Products
    • 12.4.4 Recent Developments
  • 12.5. Agilent Technologies Inc
    • 12.5.1 Company Overview
    • 12.5.2 Company Revenue
    • 12.5.3 Products
    • 12.5.4 Recent Developments
  • 12.6. BGI
    • 12.6.1 Company Overview
    • 12.6.2 Company Revenue
    • 12.6.3 Products
    • 12.6.4 Recent Developments
  • 12.7. PacBio
    • 12.7.1 Company Overview
    • 12.7.2 Company Revenue
    • 12.7.3 Products
    • 12.7.4 Recent Developments
  • 12.8. Oxford Nanopore Technologies Plc.
    • 12.8.1 Company Overview
    • 12.8.2 Company Revenue
    • 12.8.3 Products
    • 12.8.4 Recent Developments
  • 12.9. Azenta US Inc. (Genewiz)
    • 12.9.1 Company Overview
    • 12.9.2 Company Revenue
    • 12.9.3 Products
    • 12.9.4 Recent Developments
  • 12.10. CD Genomics
    • 12.10.1 Company Overview
    • 12.10.2 Company Revenue
    • 12.10.3 Products
    • 12.10.4 Recent Developments
  • 12.11. Novogene Co Ltd
    • 12.11.1 Company Overview
    • 12.11.2 Company Revenue
    • 12.11.3 Products
    • 12.11.4 Recent Developments
  • 12.12. Eurofins Genomics
    • 12.12.1 Company Overview
    • 12.12.2 Company Revenue
    • 12.12.3 Products
    • 12.12.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies

ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦